BioXL

Company Overview

Snapshot

Founded in October 2017, BioXL operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing innovative biopharma solutions for critical and underserved medical conditions.

Business overview

BioXL is a biopharmaceutical company dedicated to developing innovative solutions for critical and underserved medical conditions. Its core products include CancerPredict, a diagnostic test for breast cancer utilizing biomarkers and AI-powered software; CeaseCancer, an anti-cancer biologic drug for pancreatic cancer treatment; and NES Pharma, a drug treatment designed to prevent or slow dementia progression. The company serves the healthcare and life sciences sectors, with a focus on pharmaceuticals and addressing conditions prevalent in aging populations and women's health. BioXL operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

What is BioXL's primary focus?

BioXL is a biopharma company focused on developing innovative solutions for critical and underserved medical conditions, including cancer and dementia.

What is CancerPredict?

CancerPredict is a diagnostic test developed by BioXL that uses biomarkers and AI to predict breast cancer development, intended for integration into existing screening programs.

What is CeaseCancer?

CeaseCancer is an anti-cancer biologic drug developed by BioXL for pancreatic cancer treatment. It is an injectable drug with a unique mechanism of action that targets cancer cells without harming normal cells.

What is NES Pharma?

NES Pharma is a drug treatment developed by BioXL aimed at preventing or slowing the progression of dementia. It combines drug substances targeting glutamate excitotoxicity.

When was BioXL founded?

BioXL was founded in October 2017.